Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease. Source
No articles found.
Anavex utilizes precision genetic medicine to treat severe and devastating neurolo...
Anavex utilizes precision genetic medicine to t...
Tactile Medical is a leader in developing and marketing at-home therapy devices th...
Tactile Medical is a leader in developing and m...
Aevi Genomic Medicine is focused on translating genetic discoveries into novel the...
Aevi Genomic Medicine is focused on translating...
Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-i...
Aerpio Pharmaceuticals is a biopharmaceutical c...
Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to ...
Rexahn Pharmaceuticals is a clinical stage biop...
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company that...
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a gl...
Benitec is a biotechnology company developing a proprietary therapeutic technology...
Benitec is a biotechnology company developing a...
Join the National Investor Network and get the latest information with your interests in mind.